In this trial of 200 patients with active Cdiff infection, they were randomized to placebo or a single IV infusion of a monoclonal antibody against toxin A and B, in addition to standard treatment with either metronidazole or vancomycin. Those in the antibody group had lower risk of recurrence at 84 days (7% vs 25%) with no difference in adverse events. A single infusion of monoclonal antibody significantly reduces the risk of recurrent Cdiff infection (abstract).
This large systematic review found rectal NSAIDs significantly reduced the risk of post-ERCP pancreatitis compared to pancreatic duct stents (abstract).
This large population-based cohort found the most common causes of drug induced liver injury to be augmentin and diclofenac, followed by herbal and nutritional supplements (abstract).
This large trial of patients with a relative contraindication for enteral feeds were randomized to early TPN or usual care. There were no differences in the groups in 60 day mortality or LOS, but those on TPN did have a shorter time ventilated and less muscle/fat loss. It is unclear based on this trial if […]